Masayuki Kurosaki

List of Publications by Year
in descending order

44 papers	1,226 citations	331259 21 h-index	395343 33 g-index
44 all docs	44 docs citations	44 times ranked	1494 citing authors

#	Article	IF	Citations
1	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology, 2010, 52, 518-527.	3.6	265
2	*Wisteria floribunda* agglutinin positive human Macâ€2â€binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatology Research, 2015, 45, E82-8.	1.8	55
3	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. Journal of Gastroenterology, 2014, 49, 1495-1503.	2.3	44
4	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE, 2020, 15, e0231828.	1.1	42
5	Sofosbuvirâ€"velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatology International, 2018, 12, 356-367.	1.9	41
6	*Wisteria floribunda* agglutininâ€positive Macâ€2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by directâ€acting antivirals for hepatitis C virus. Hepatology Research, 2018, 48, 1131-1139.	1.8	40
7	Longitudinal association of magnetic resonance elastographyâ€associated liver stiffness with complications and mortality. Alimentary Pharmacology and Therapeutics, 2022, 55, 292-301.	1.9	38
8	Naturally occurring, resistanceâ€associated hepatitis C virus NS5A variants are linked to interleukinâ€28B genotype and are sensitive to interferonâ€based therapy. Hepatology Research, 2015, 45, E115-21.	1.8	37
9	Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS ONE, 2016, 11, e0165339.	1.1	36
10	Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of Gastroenterology, 2018, 53, 1142-1150.	2.3	36
11	East Asia expert opinion on treatment initiation for chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2020, 52, 1540-1550.	1.9	36
12	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2960-2966.	1.4	36
13	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	1.7	34
14	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0154558.	1.1	34
15	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€"Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers, 2019, 11, 1517.	1.7	30
16	Realâ€world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatology Research, 2019, 49, 264-270.	1.8	27
17	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Annals of Laboratory Medicine, 2021, 41, 16-24.	1.2	27
18	Nonâ€alcoholic fatty liver disease fibrosis score and FIBâ€4 scoring system could identify patients at risk of systemic complications. Hepatology Research, 2015, 45, 667-675.	1.8	26

#	Article	IF	Citations
19	Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatology Research, 2022, 52, 497-507.	1.8	26
20	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. Journal of Viral Hepatitis, 2019, 26, 893-899.	1.0	25
21	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. Journal of Gastroenterology, 2021, 56, 470-478.	2.3	25
22	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. Journal of Hepatology, 2022, 77, 967-977.	1.8	25
23	Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Scientific Reports, 2019, 9, 10109.	1.6	24
24	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis <scp>C</scp> patients. Hepatology Research, 2014, 44, 720-727.	1.8	22
25	Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatology Research, 2019, 49, 33-41.	1.8	22
26	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clinical Infectious Diseases, 2021, 73, e3349-e3354.	2.9	21
27	Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC. Hepatology Research, 2020, 50, 1004-1014.	1.8	20
28	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers, 2019, 11, 1256.	1.7	17
29	Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. Clinical Gastroenterology and Hepatology, 2019, 17, 2616-2618.	2.4	17
30	Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. Hepatology Research, 2018, 48, 746-756.	1.8	11
31	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. Journal of Medical Ultrasonics (2001), 2021, 48, 481-487.	0.6	11
32	Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Reports, 2020, 2, 100138.	2.6	10
33	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatology Communications, 2022, 6, 461-472.	2.0	10
34	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. Clinical Gastroenterology and Hepatology, 2023, 21, 380-387.e3.	2.4	10
35	Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. Diagnostics, 2020, 10, 173.	1.3	8
36	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. International Journal of Molecular Sciences, 2021, 22, 40.	1.8	8

#	Article	IF	Citations
37	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. Journal of Viral Hepatitis, 2021, 28, 787-794.	1.0	7
38	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Î±-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. International Journal of Molecular Sciences, 2020, 21, 3640.	1.8	5
39	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. Hepatology Research, 2020, 50, 996-999.	1.8	5
40	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 2022, 14, 2975.	1.7	5
41	Impact of antiviral therapy for disease progression and nonâ€‘invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis. Hepatology Research, 2022, 52, 665-676.	1.8	4
42	Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.. Journal of Clinical Oncology, 2019, 37, 323-323.	0.8	3
43	Validation of magnetic resonance elastography plus FIBâ€‘4 for significant fibrosis in nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2022, , .	1.4	1
44	Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients. Hepatology Research, 2021, 51, 1170-1171.	1.8	0